• Alma Lasers (Buffalo Grove, Illinois) reported that it has received clearance from the FDA to market the Accent dual mode radio frequency (RF) system in the U.S. Indicated for the treatment of wrinkles and rhytids, the accent system has been used by medical professionals to treat a variety of dermatological and aesthetic conditions. The system combines two RF modes into one device. Each mode is delivered by a discrete handpiece to enable volumetric RF thermotherapy at different tissue depths within the body. Alma Lasers makes laser, light-based and radio frequency technologies used in aesthetic medicine.

• DecisionView (San Francisco) reported the availability of StudyOptimizer 3.5 for clinical trials. StudyOptimizer 3.5 automates the clinical recruitment process with integrated predictive modeling, analytics, simulation and rich visualization capabilities resulting in shorter cycle times, reduced recruitment costs and improved clinical operational efficiencies, according to the company. The new version delivers recruitment planning to include recruitment rate variables such as seasonality for developing robust clinical recruitment plans; advanced simulation modeling and predictive analytics that enable clinical study managers to model course corrections and alternative recruitment strategies; and rich interactive visualizations, including performance alerts and dashboards at the study, country and site level. DecisionView provides business performance optimization software for the life sciences industry.

No Comments